ClinicalTrials.gg
CompletedNCT01914653Updated Oct 9, 2017

SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support and Repair in Breast Reconstruction

An interventional study of Silk surgical mesh in Breast Reconstruction, sponsored by Sofregen Medical, Inc.. Completed at 1 site in Israel. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-09.

Sponsored by Sofregen Medical, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Prospective, single center, postmarket clinical study to obtain clinical experience with the use of SERI® Surgical Scaffold for soft tissue support and repair in breast reconstruction.

02

Conditions studied

  • Breast Reconstruction
03

In context

Lead sponsor

Sofregen Medical, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for enrollment, the subject must:

  1. Be female, ≥ 18 years of age
  2. If the subject is a female of childbearing potential, have a pregnancy test evaluated as negative prior to surgery, per the site's standard of care
  3. Have a nicotine test evaluated as negative prior to surgery and agree not to smoke for the duration of the study
  4. Be willing to undergo mastectomy with healthy, well-vascularized skin flaps anticipated by the surgeon
  5. Be eligible to enroll in one of the following three cohorts:

1. Subject had radiation therapy (XRT) prior to direct-to-implant (DTI) reconstruction, but will not have XRT following reconstruction;

2. Subject did not have XRT prior to DTI reconstruction and will not have XRT following reconstruction;

3. Subject did not have XRT prior to DTI reconstruction, but will have XRT following reconstruction.

Exclusion criteria

Exclusion Criteria:

To be eligible for enrollment, the subject must not:

  1. Have collagen-vascular, connective tissue, or bleeding disorders
  2. Have any disease, including uncontrolled diabetes, which is clinically known to impact wound healing ability
  3. Have an autoimmune disease, an immune deficiency, or is on immune-suppression drugs for reasons other than current treatment for breast cancer
  4. Have a BMI that is ≥ 32
  5. Have a nicotine test evaluated as positive prior to surgery or unwilling to quit smoking for the duration of the study
  6. Currently have an alcohol/substance abuse problem or have had a relapse within 1 year prior to screening visit
  7. Be pregnant, lactating, or expecting to be within the next 24 months
  8. Have concomitant unrelated condition of breast/chest wall/skin (e.g. significant chest wall abnormalities including pectus excavatum or pectus carinatum)
  9. Require the use of any additional implant for soft tissue support of the contralateral non-study breast, except in bilateral breast reconstructions, where the use of SERI® Surgical Scaffold is allowed
  10. Have had a prior soft tissue support implant
  11. If enrolled into the Pre-Radiated cohort, have had recent radiation (\< 1 year) to the breast/chest wall
  12. If enrolled into the Post-Radiated cohort, radiation to the breast/chest wall is planned more than 1 year from the time of SERI® Surgical Scaffold placement
  13. Have clinical evidence of severe radiation tissue damage (e.g. pigmentation, indentation, atrophy, no elasticity to skin of radiated breast) from previous XRT to the breast/chest wall
  14. Have large or multiple scars on the breast(s) that may interfere with blood supply to the mastectomy flaps
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Pre-radiated

    Device: Silk surgical mesh

  • Experimental
    Not radiated

    Device: Silk surgical mesh

  • Experimental
    Post-radiated

    Device: Silk surgical mesh

Interventions

  • DeviceSilk surgical mesh

    A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair

06

What researchers measure

Primary outcomes

  1. Incidence of Implant Loss

    Implant Loss will be defined as situations in which the breast implant is removed and not immediately replaced.

    Time frame: 24 months postoperatively

07

Study locations

1 site
  • Assuta Medical Center
    Tel Aviv, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01914653
Lead sponsor
Sofregen Medical, Inc.
Responsible party
Sponsor
First posted
Aug 2, 2013
Start date
Jun 2013
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Oct 9, 2017

Study contacts

Medical Director
study director · Allergan Medical
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion